A new method in the treatment of adolescent HIV has been uncovered.
Raltegravir, an antiretroviral medication known to delay the spread of HIV, was administered to 95 people in the age group of 2-18 years. The subjects had previously been treated with other specimens of HIV medications.
After 24 weeks, 53% of the participants showed an indiscernible amount of HIV in their blood. Something had definately changed in the inherent structure the disease weaves inside the body. Dr Sharon Nachman, lead researcher of the study, says that Raltegravir is an important new option for children with HIV. “The drug is also effective against the virus regardless where the child lives around the world. The data also shows no significant toxicities or interactions with other HIV medications.”
Children and adolescents receive Raltegravir in the form of a pill, while younger patients are given the drug in a chewable form.
The drug is approved by the Food and Drug Administration for use with other retroviral medications to treat children and teenagers between 2 to 18 years of age.